Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Inclusion Criteria:

* Meet the American College of Rheumatology criteria for the diagnosis of SLE.
* The test for plasma CMV DNA viral load is positive.
* Age: 18 to 65 years, weight 45-80kg, male or female, gender ratio is not limited.
* Apply corticosteroid less than 1.0mg/kg/d.
* Written informed consent form.

Exclusion Criteria:

* Inability to comply with IL-2 treatment regimen;
* Other active infections. (hepatitis B or C virus, Epstein-Barr virus, human immunodeficiency virus, Mycobacterium tuberculosis or pneumocystis carinii pneumonia)
* Any anti-CMV vaccine within 6 months;
* History of intravenous immunoglobulin (IVIG) or leflunomide within 6 months prior to randomization, and those who have undergone plasmapheresis;
* Active severe neuropsychiatric manifestations of SLE;
* Severe chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III NYHA), hepatic insufficiency (transaminases\> 3N));
* Severe complications. (respiratory failure, heart failure or toxic shock)
* Complicated with other autoimmune diseases;
* Cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or Basocellular carcinoma);
* Pregnancy or lactation in females.
* Mental disorder or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give information;
* Participate in other clinical trial within 3 months.